Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings: 2015-2024

Historic Retained Earnings for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$2.2 billion.

  • Intellia Therapeutics' Retained Earnings fell 21.76% to -$2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 21.76%. This contributed to the annual value of -$2.2 billion for FY2024, which is 31.30% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Retained Earnings is -$2.2 billion, which was down 31.30% from -$1.7 billion recorded in FY2023.
  • Intellia Therapeutics' Retained Earnings' 5-year high stood at -$435.1 million during FY2020, with a 5-year trough of -$2.2 billion in FY2024.
  • Over the past 3 years, Intellia Therapeutics' median Retained Earnings value was -$1.7 billion (recorded in 2023), while the average stood at -$1.7 billion.
  • Data for Intellia Therapeutics' Retained Earnings shows a maximum YoY tumbled of 67.45% (in 2022) over the last 5 years.
  • Intellia Therapeutics' Retained Earnings (Yearly) stood at -$435.1 million in 2020, then slumped by 61.57% to -$703.0 million in 2021, then crashed by 67.45% to -$1.2 billion in 2022, then slumped by 40.88% to -$1.7 billion in 2023, then tumbled by 31.30% to -$2.2 billion in 2024.